Vertex announces european commission approval for kalydeco® to treat infants with cystic fibrosis ages 1 month and older

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european commission has granted approval for the label expansion of kalydeco® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (cf) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: r117h, g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r. “today's approval is an important milestone for the cys.
VRTX Ratings Summary
VRTX Quant Ranking